Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Rheumatoid Arthritis | Emerging Therapies | Olumiant (baricitinib) | US | Wave 1 | 2018
MARKET OUTLOOK Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after the launch of Pfizer’s Jak…
Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 2 | 2018
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only oral targeted therapy approved for this indication besides Celgene’s PDE-…
Migraine | Emerging Therapies | Migraine Prophylaxis | Erenumab-Migraine Prevention | US | Wave 1 | 2018
Market Outlook The migraine prophylaxis market stands poised for disruption with the launch of Amgen/Novartis’s Aimovig (erenumab) in May 2018 and three additional anti-CGRP monoclonal…
Multiple Sclerosis (Primary Progressive) | Emerging Therapies | Ocrevus (ocrelizumab) | Wave 3 | US | 2018
Market Overview In a landmark FDA ruling in March 2017, Ocrevus became the first disease-modifying therapy (DMT) approved for the treatment of primary-progressive multiple sclerosis (PP-MS)…
Multiple Sclerosis (Relapsing-Remitting) | Emerging Therapies | Ocrevus (ocrelizumab) | US | Wave 3 | 2018
Market Overview Ocrevus is the latest disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States, and easily one of the most…
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Emerging Therapies – Chimeric Antigen (CAR) T-Cell Therapy – Special Topics – US (Wave 2)
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
Atopic Dermatitis/Atopic Eczema | Emerging Therapies | Dupixent (dupilumab) | US | Wave 3 | 2018
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…
Atopic Dermatitis | Emerging Therapies | Eucrisa (crisaborole) | US | Wave 3 | 2018
Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…
Multiple Sclerosis | Emerging Therapies | Ocrevus in PP-MS (Wave 2) | US – 2017
In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of…
